CENEXA   05419
CENTRO DE ENDOCRINOLOGIA EXPERIMENTAL Y APLICADA
Unidad Ejecutora - UE
artículos
Título:
Hospitalization costs for heart failure in people with type 2 diabetes: cost-effectiveness of its prevention measured by a simulated preventive treatment
Autor/es:
CAPORALE JE; ELGART J; PFIRTER G; MARTÍNEZ P; VIÑES G; INSÚA J; GAGLIARDINO JJ
Revista:
VALUE IN HEALTH
Editorial:
WILEY-BLACKWELL PUBLISHING, INC
Referencias:
Lugar: Londres; Año: 2011 vol. 14 p. 20 - 23
ISSN:
1098-3015
Resumen:
Objectives: To estimate the cost-consequence of interventions to prevent hospitalizations for heart failure (HF) in people with type 2 diabetes (T2DM). Methods: In HF events (63) from T2DM hospitalizations (462) recorded in an Argentine hospital (March 2004-April 2005), we verified a) the presence of one metabolic HF predictor (HbA1c value) before hospitalization, and b) in a simulation model, the resources necessary for its prevention controlling such predictor during 6 months before and after the event. Sensitivity analysis of HF risk reduction, hospitalization cost and cost of different treatments to achieve HbA1c ≤ 7% was performed with a Monte Carlo simulation (10,000 iterations). Results: Heart failure represented 14% of hospitalizations, with a 44% re-hospitalization rate for the same cause. Since the total estimated cost for an HF hospitalization event was $437.31, the prevention attained using our simulated treatment was $2,326.51. The number needed to treat (NNT) to prevent an HF event under any of the proposed alternatives to reduce HbA1c would be 3.57 (95% CI: 2.00 – 16.67). The additional cost of the simulated treatment versus the real one oscillates between $6,423.91 and $8,455.68. Conclusion: HbA1c control to reduce the number of HF events would be economically beneficial for health care payers.